About InVivoSIM anti-human integrin α4β7 (LPAM-1) (Vedolizumab Biosimilar) This non-therapeutic biosimilar antibody uses the same variable regions as the therapeutic antibody Vedolizumab making it ideal for research use. This Vedolizumab biosimilar reacts with integrin α4β7. The 130 kDa integrin β7 chain associates with the 150 kDa integrin α4 (CD49d) chain to form LPAM-1, a member of the Ig superfamily. LPAM-1 is expressed by peripheral lymphocytes, small subsets of thymocytes, and bone marrow progenitors. LPAM-1 binds VCAM-1 (CD106), MAdCAM-1, and fibronectin and facilitates lymphocyte adhesion and migration to the intestine and associated lymphoid tissues. Vedolizumab binds specifically to the α4β7 integrin heterodimer, but not to the functionally distinct α4β1 or αEβ7 integrin heterodimers, thereby inhibiting the binding of α4β7-expressing cells to MAdCAM-1 and fibronectin, but not to VCAM-1. InVivoSIM anti-human integrin α4β7 (LPAM-1) (Vedolizumab Biosimilar) Specifications IsotypeHuman IgG1, κ Recommended Isotype Control(s)RecombiMAb human IgG1 (LALA-PG) isotype control, anti-hen egg lysozyme Recommended Dilution BufferInVivoPure pH 7.0 Dilution Buffer ImmunogenHuman integrin α4β7 (LPAM-1) Reported ApplicationsFunctional assays ELISA Western blot FormulationPBS, pH 7.0 Contains no stabilizers or preservatives Endotoxin<0.5EU/mg (<0.0005EU/μg) Determined by LAL gel clotting assay Aggregation<5% Determined by SEC Purity>95% Determined by SDS-PAGE Sterility0.2 μm filtration ProductionPurified from cell culture supernatant in an animal-free facility PurificationProtein A Molecular Weight150 kDa StorageThe antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
